Millipore Sigma Vibrant Logo

119137 Adenosine A2A Receptor Agonist I, CGS 21680, Hydrochloride - CAS 124182-57-6 - Calbiochem

Adenosine A2A Receptor Agonist I, CGS 21680, Hydrochloride - CAS 124182-57-6 - Calbiochem: のSDS（安全データシート）、CoA（試験成績書）およびCoQ（品質証明書）、カタログなど製品関連の技術資料を入手いただけます。

同義語: CGS-21680, CGS21680, 3-(4-(2-((6-amino-9-((2R,3R,4S,5S)-5-(ethylcarbamoyl)-3,4-dihydroxytetrahydrofuran-2-yl)-9H-purin-2-yl)amino)ethyl)phenyl)propanoic acid

View This Product on Sigma-Aldrich
119137
価格＆在庫状況を照会

概要

Replacement Information

価格＆在庫状況

カタログ番号 在庫状況包装 Qty/Pk 価格 数量
119137-5MGCN
在庫状況検索中…
—
現在国内在庫なし 現在国内在庫なし
現在国内在庫有り 
販売中止
在庫僅少
現在国内在庫あり
    Remaining : Will advise
      Remaining : Will advise
      注文対象外
      お問合せください
      Contact Customer Service

      		 ｶﾞﾗｽﾋﾞﾝ 5 mg
      価格を検索中…
      価格が見つかりません
      Minimum Quantity needs to be mulitiple of
      Maximum Quantity is
      弊社照会 詳細を表示　
      値引
      ()
       
      —
      弊社照会
      		 —
      Description
      OverviewA xanthin derivative that acts as a potent agonist of adenosine A2A receptors (Ki = 27 nM). Exhibits reduced affinity for A2B receptors (Ki = 67 nM), but offers greater selectivity over A1R (Ki = 290 nM) and A3R (88.8 µM). Exerts an anti-inflammatory effect during chronic inflammation and ameliorates the tissue damage associated with collagen-induced arthritis. Also shown to reduce CCR7 Protein Expression in THP1 macrophages. Shown to delay the progressive deterioration of motor performance and prevent a reduction in brain weight in murine model of Huntington's disease. Please note that the molecular weight for this compound is batch-specific due to variable water content. Please refer to the vial label or the certificate of analysis for the batch-specific molecular weight. The molecular weight provided represents the baseline molecular weight without water.
      Catalogue Number119137
      Brand Family Calbiochem®
      SynonymsCGS-21680, CGS21680, 3-(4-(2-((6-amino-9-((2R,3R,4S,5S)-5-(ethylcarbamoyl)-3,4-dihydroxytetrahydrofuran-2-yl)-9H-purin-2-yl)amino)ethyl)phenyl)propanoic acid
      References
      ReferencesWillians, A. J., et al. 2012. Inflammation. 35, 614.
      Mazzon, E. et al. 2011. J Rheumatol. 38, 2119,
      Martire, A., et al. 2007. Neurosci Lett. 417, 78.
      Chou, S. Y., et al, 2005. Journ Neurochem. 93, 310.
      Klotz, K. N., et al. 2000. Naunyn Schmiedebergs Arch Pharmacol.362 382.
      Phillis, J. W., et al. 1990.Brain Res. 509, 328.
      Product Information
      CAS number124182-57-6
      FormWhite solid
      FormulationSupplied as a hydrochloride salt.
      Hill FormulaC₂₃H₂₉N₇O₆ • HCl
      Chemical formulaC₂₃H₂₉N₇O₆ • HCl
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Biological Information
      Purity≥96% by HPLC
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Shipped at Ambient Temperature or with Blue Ice or with Dry Ice
      Toxicity Standard Handling
      Storage -20°C
      Protect from Light Protect from light
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      カタログ番号 GTIN
      119137-5MGCN 04055977223330

      Documentation

      Adenosine A2A Receptor Agonist I, CGS 21680, Hydrochloride - CAS 124182-57-6 - Calbiochem (M)SDS

      タイトル

      英語版製品安全データシート（(M)SDS） 

      Adenosine A2A Receptor Agonist I, CGS 21680, Hydrochloride - CAS 124182-57-6 - Calbiochem 試験成績書（CoA）

      タイトルロット番号
      119137

      参考資料

      参考資料の概要
      Willians, A. J., et al. 2012. Inflammation. 35, 614.
      Mazzon, E. et al. 2011. J Rheumatol. 38, 2119,
      Martire, A., et al. 2007. Neurosci Lett. 417, 78.
      Chou, S. Y., et al, 2005. Journ Neurochem. 93, 310.
      Klotz, K. N., et al. 2000. Naunyn Schmiedebergs Arch Pharmacol.362 382.
      Phillis, J. W., et al. 1990.Brain Res. 509, 328.
      データシート

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision14-November-2019 JSW
      SynonymsCGS-21680, CGS21680, 3-(4-(2-((6-amino-9-((2R,3R,4S,5S)-5-(ethylcarbamoyl)-3,4-dihydroxytetrahydrofuran-2-yl)-9H-purin-2-yl)amino)ethyl)phenyl)propanoic acid
      DescriptionA xanthin derivative that acts as a potent agonist of adenosine A2A receptors (Ki = 27 nM). Exhibits reduced affinity for A2B receptors (Ki = 67 nM), but offers greater selectivity over A1R (Ki = 290 nM) and A3R (88.8 µM). Exerts an anti-inflammatory effect during chronic inflammation and ameliorates the tissue damage associated with collagen-induced arthritis. Also shown to reduce CCR7 Protein Expression in THP1 macrophages. Shown to delay the progressive deterioration of motor performance and prevent a reduction in brain weight in murine model of Huntington's disease.
      FormWhite solid
      FormulationSupplied as a hydrochloride salt.
      Intert gas (Yes/No) Packaged under inert gas
      CAS number124182-57-6
      Chemical formulaC₂₃H₂₉N₇O₆ • HCl
      Structure formulaStructure formula
      Purity≥96% by HPLC
      SolubilityDMSO (100 mM)
      Storage Protect from light
      -20°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Toxicity Standard Handling
      ReferencesWillians, A. J., et al. 2012. Inflammation. 35, 614.
      Mazzon, E. et al. 2011. J Rheumatol. 38, 2119,
      Martire, A., et al. 2007. Neurosci Lett. 417, 78.
      Chou, S. Y., et al, 2005. Journ Neurochem. 93, 310.
      Klotz, K. N., et al. 2000. Naunyn Schmiedebergs Arch Pharmacol.362 382.
      Phillis, J. W., et al. 1990.Brain Res. 509, 328.